Findings

What do systematic reviews say?

7 questions · 7 findings · 2 reviews

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 28.6%High 1 · 14.3%

Adverse events · People with quiescent Crohn's disease (ileocolic resection)

The review found no eligible studies for this question.

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events · Participants with Crohn's disease in remission

Adalimumab showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
RR 1.01 [0.94, 1.09]
4 studies · 1012 participants
High

Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)

The review found no eligible studies for this question.

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · Participants with Crohn's disease in remission

Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
RR 0.56 [0.39, 0.8]
4 studies · 1012 participants
Moderate

Adverse events · Patients with ileal pouch‐anal anastomosis

The review found no eligible studies for this question.

1 finding from 1 review

Withdrawals due to adverse events · People with quiescent Crohn's disease (ileocolic resection)

The review found no eligible studies for this question.

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Withdrawals due to adverse events · Participants with Crohn's disease in remission

Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
RR 0.59 [0.38, 0.91]
4 studies · 1012 participants
Moderate